MedTrace Logo

Infusion of Apomorphine: Long-term Safety Study

NCT02339064 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2025-06-19

No results posted yet for this study

Summary

This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therapy for PD.

Conditions

  • Idiopathic Parkinson's Disease

Interventions

DRUG

apomorphine infusion

Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device

Sponsors & Collaborators

  • MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Gianpiera Ceresoli-Borroni, PhD · Supernus Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2018-12-31
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02339064 on ClinicalTrials.gov